EGFR and non-small cell lung carcinoma: For example, Westerink et al. used the median PFS as a proxy for the DOT of afatinib for first-line EGFR-mutant non-small-cell lung cancer [26], while Mennini et al. used the same assumption in relation to the use of cetuximab for recurrent and/or metastatic head and neck squamous cell cancer [27].